J&J warns generics will bite its pharma unit in the second halfJohnson & Johnson has kicked off the interim results season with a warning that low-cost generic and biosimilar Share XJ&J warns generics will bite its pharma unit in the second halfhttps://pharmaphorum.com/news/jj-warns-generics-will-bite-its-pharma-unit-in-the-second-half/
Sanofi expects growth as rare disease drugs boost earningsSanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company Share XSanofi expects growth as rare disease drugs boost earningshttps://pharmaphorum.com/news/sanofi-expects-growth-as-rare-disease-drugs-boost-earnings/
